Navigation Links
Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Date:4/14/2009

LA JOLLA, Calif., April 14 /PRNewswire/ -- Zenobia Therapeutics, Inc., the leader in fragment-based lead discovery for diseases of the central nervous system, announced successful completion of the first phase of its services agreement with Syntonix Pharmaceuticals, a wholly-owned subsidiary of Biogen Idec (Nasdaq: BIIB). As part of the agreement, Syntonix gains access to Zenobia's technology and expertise in structural biology, crystallization and X-ray structure determination. Zenobia completed three unique protein structures during the first five months of the agreement. The agreement includes research funding and milestone payments.

"Syntonix challenged us with a difficult program, and through close collaboration between our scientists, we are pleased to deliver results," said Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia.

The program required dedicated expertise in protein crystallization including specialized techniques and multiple rounds of optimization.

"It was a challenging target to crystallize, with more than 800 conditions being screened followed by careful optimization of multiple parameters, which was a key for successful structure determination," said Vandana Sridhar, head of Zenobia's crystallization group.

Zenobia has rapid access to high-energy synchrotron sources for data collection through an agreement with Shamrock Biostructures, located near the Advanced Photon Source (APS) in Chicago, IL.

"Synchrotron radiation was required for this program, and we are fortunate to have routine access to the only third-generation synchrotron in the U.S. through our agreement with Shamrock," said Dr. Nienaber.

"Having access to these new experimental crystal structures will allow us to more efficiently design and develop our internal drug
'/>"/>

SOURCE Zenobia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
2. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
4. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
5. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
6. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
7. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
8. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
9. Arno Therapeutics Reports 2008 Year-End Financial Results
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders announced ... as Chief Operating Officer.  Reporting directly to ... Officer, Robert will oversee the planned global commercial ... for LAL Deficiency, and will have responsibility for ...
(Date:9/21/2014)... Chemical Sciences play a significant role in meeting ... safe water, healthy food, and dependable medicine from ... educators, and scientists have a great role in ... for the national development, and to foster research ... emerging Sciences, accelerating with a tremendous speed to ...
(Date:9/19/2014)... BRISBANE, Calif., Sept. 19, 2014  InterMune, Inc. (Nasdaq: ... into a Memorandum of Understanding to settle the litigation ... Agreement and Plan of Merger dated as of August ... and InterMune, Inc.  As one term of the Memorandum ... disclosures set forth in the attached exhibit reflecting the ...
(Date:9/19/2014)... 19, 2014 Follow us ... to revolutionize the world has attracted diverse players ... small start-ups. The early years of nanotechnology development ... due to the high risks involved, which deterred ... for this evolving technology have been growing over ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... , , Mark Churchill 1 , Mark Harrison 1 , , ... , 1 Thermo Finnigan, Stafford House, 1 Boundary Park, Boundary Way, ... Aker University Hospital, Hormone Laboratory, Section for Doping Analysis,Trondheimsveien, , N-0514, Oslo, Norway, ... , Monitoring Clenbuterol in Humans , , , ...
... , , , , , , , ... , Features and benefits , , , , , ... transfection of siRNA for effective gene silencing , Quick and easy setup ... for absence of RNase activity , , , , , ...
... , , , , QIAshredder spin columns are designed for simple and rapid ... , , , , ... , , , ... tissue lysates, , plant cell or tissue lysates, white blood cell lysates, ...
Cached Biology Technology:Improved Quantitative Selectivity of Clenbuterol in Human Urine using , High Resolution on the TSQ Quantum Mass Spectrometer 2Improved Quantitative Selectivity of Clenbuterol in Human Urine using , High Resolution on the TSQ Quantum Mass Spectrometer 3Improved Quantitative Selectivity of Clenbuterol in Human Urine using , High Resolution on the TSQ Quantum Mass Spectrometer 4Improved Quantitative Selectivity of Clenbuterol in Human Urine using , High Resolution on the TSQ Quantum Mass Spectrometer 5TransMessenger Transfection Reagent 2TransMessenger Transfection Reagent 3QIAshredder Homogenizer 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... The sense of fairness did not evolve for the ... reap the benefits of continued cooperation, so say Frans ... a review article about inequity aversion (IA), which is ... review is published in Science . , ... 35 IA-related studies to address their hypothesis that it ...
(Date:9/18/2014)... A new GSA Bulletin study uses ... Rio Puerco and Chaco Wash in northern New Mexico, ... salt cedar and willow, investigators were able to precisely ... They then combined this data with aerial imagery, LiDAR, ... of these arroyos. , Arroyos are deep, oversized channels ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... When researchers sequence the RNA of cancer cells, they can ... RNA. That can help lead them to the gene or protein ... a few known instigators, what does it mean? Is there more ... fast enough? What part of the biological equilibrium is off? ...
... the first time that primates modify their body movements to ... Humans unconsciously modify their movements to be in synchrony with ... in step or clap in unison at the end of ... facilitate human interaction. Researchers from the RIKEN Brain Science Institute ...
... patients with an inherited heart condition known as arrhythmogenic ... problem until they,re in their early 20s. The lack ... for researchers to study how ARVD/C evolves or to ... 2012 Nobel Prize winner Shinya Yamanaka, M.D., Ph.D., helps ...
Cached Biology News:New technique sheds light on RNA 2Primates too can move in unison 2Patients' own skin cells are transformed into heart cells to create 'disease in a dish' 2Patients' own skin cells are transformed into heart cells to create 'disease in a dish' 3
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... variant: With the macro- and ... and Skoog (1962) and the ... et al. (1968). Preparation Quantity ... grams of powder per liter ...
... CBED Maxi Kit provides a fast and ... protein solutions for buffer exchange, and for removing ... kit is based on spin-column chromatography using Norgens ... such as MgCl 2 , NaCl, KCl, CaCl ...
Biology Products: